Lund-based MedVasc AB, a Swedish MedTech firm, introduced at the moment the profitable closing of a €917k financing spherical to help the ultimate product improvement section for his or her catheter system and preparation for FDA regulatory approval in the USA.
The financing spherical attracted each current house owners and new buyers.
“We’re very happy with the continued confidence from our buyers,” says Cathrin Johansson, CEO of MedVasc AB. “This funding offers us the chance to take decisive steps in direction of reaching the US market, which is a crucial milestone in our progress journey.”
MedVasc AB was based in 2013 by Michael Åkesson and has over the last years, developed a ultimate prototype, been granted patents and emblems in all prioritised markets, and carried out a first-in-man medical examine.
Åkesson is a senior marketing consultant of interventional radiology and has an expertise of over twenty years with catheter based mostly remedies and prognosis. Beforehand he was the Head of the Division of Endovascular Surgical procedure on the Vascular Division, College Hospital SUS Malmö. He now works as a senior marketing consultant on the Scandinavian Venous Centre, Malmö.
He’s the principle proprietor of MedVASC AB and the inventor behind Solutio.
MedVasc has developed and patented the medical system Solutio, designed to enhance the anaesthetic process when treating varicose veins. For investigational use solely. The Solutio catheter has not been evaluated by the FDA and isn’t but out there on the market within the USA.
Solutio is designed to allow secure and exact native anesthesia throughout minimally invasive vascular procedures, e.g. varicose veins, (appropriate with thermal ablation therapy fibers), providing a brand new stage of management and affected person consolation for clinicians treating persistent venous issues.
The first focus of the funding shall be to fund the manufacturing and testing of the ultimate design of Solutio, required for FDA clearance. Regulatory submission is deliberate for the primary half of 2026.
As well as, MedVasc will elevate a further spherical throughout 2025 for investments in medical and preclinical actions required for FDA clearance.
MedVasc can also be collaborating in SmiLe’s incubator programme – additionally based mostly in Lund. SmiLe is a number one enterprise hub that specialises in advancing life science and FoodTech startups from idea to commercialisation. Up to now, their flagship incubator programme has supported over 110 startups, facilitating their collective acquisition of greater than €1.05 billion in enterprise capital and contributing to 21 profitable IPOs.
